• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Intellia Therapeutics downgraded by Goldman with a new price target

    2/23/24 9:25:16 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NTLA alert in real time by email
    Goldman downgraded Intellia Therapeutics from Buy to Neutral and set a new price target of $32.00 from $136.00 previously
    Get the next $NTLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTLA

    DatePrice TargetRatingAnalyst
    4/21/2025$21.00Peer Perform → Outperform
    Wolfe Research
    3/5/2025$30.00Buy
    H.C. Wainwright
    2/28/2025$45.00 → $13.00Overweight → Neutral
    Analyst
    2/28/2025$9.00Neutral → Sell
    Goldman
    1/27/2025$56.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    2/23/2024$136.00 → $32.00Buy → Neutral
    Goldman
    2/15/2024Peer Perform
    Wolfe Research
    4/13/2023$66.00Buy
    Canaccord Genuity
    More analyst ratings

    $NTLA
    SEC Filings

    See more
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      6/16/25 7:00:17 AM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Intellia Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

      6/12/25 4:31:54 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 filed by Intellia Therapeutics Inc.

      S-8 - Intellia Therapeutics, Inc. (0001652130) (Filer)

      6/11/25 5:14:02 PM ET
      $NTLA
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care